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Background: Tedizolid is a novel oxazolidinone antibacterial with potent activity against a wide range of
Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Although tedizolid is approved by the US Food and Drug Administration (FDA) for treatment of patients with acute
bacterial skin and skin structure infection, commercial susceptibility testing products for tedizolid are not currently
available. This study evaluated the usefulness of applying linezolid susceptibility test results as a surrogate for predicting
susceptibility to tedizolid in clinically significant Gram-positive pathogens.
Methods: Gram-positive isolates (N = 10,702) were obtained from annual surveillance programs conducted between
2009 and 2012, from 3 tedizolid clinical trials, and from a preclinical study of the antibacterial activity of tedizolid.
Susceptibility testing of linezolid and tedizolid was performed using the reference broth microdilution method in
accordance with Clinical and Laboratory Standards Institute methods.
Results: The minimum inhibitory concentration (MIC) distribution for tedizolid and linezolid against this set of isolates
was consistent with that of previous reports. Scatter plot analysis of relevant subsets of organisms was performed and
showed high categorical agreement between linezolid and tedizolid MIC results (>99% for staphylococci and
streptococci; >98% for enterococci). Very major error rates (ie, tedizolid false-susceptible errors) were very low and
within acceptable limits for a surrogate agent: S. aureus and other staphylococcal species, 0%; Enterococcus spp, 0.2%;
and Streptococcus spp, 0%.
Conclusions: High categorical agreement between MIC values for tedizolid and linezolid and low very major error
rates were shown for all organism groups tested, supporting the use of linezolid as a reliable surrogate for tedizolid
susceptibility testing.
Keywords: Tedizolid, Linezolid, Oxazolidinone, Staphylococcus aureus, Antimicrobial susceptibility testing, Surrogate
testing, Class representativeBackground
Tedizolid phosphate is a novel oxazolidinone prodrug
antibacterial that is rapidly converted by endogenous
phosphatases to the active moiety tedizolid. Tedizolid
has potent activity against a wide range of Gram-positive
pathogens, including methicillin-resistant Staphylococcus
aureus (MRSA) and vancomycin-resistant enterococci
(VRE) [1-4]. The efficacy of tedizolid phosphate 200 mg
once daily for 6 days was shown to be noninferior to* Correspondence: gzurenko@zmlconsulting.com
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unless otherwise stated.linezolid 600 mg twice daily for 10 days in each of 2
phase 3 clinical trials in patients with acute bacterial skin
and skin structure infection (ABSSSI) [5,6]. In June 2014,
the US Food and Drug Administration (FDA) approved
tedizolid phosphate for treatment of patients with ABSSSI
caused by certain susceptible Gram-positive pathogens [7].
For new antimicrobial agents, availability of commercial
susceptibility testing products always lags behind drug
approval by regulatory authorities because manufacturers
of susceptibility testing products cannot seek FDA clear-
ance to market their products until after drug approval.
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an established agent from the same or similar class is
often used as a surrogate to predict the susceptibility
of clinical isolates to the new agent. Examples include
the use of ceftriaxone for cefpodoxime [8]; carbapenem
and third- and fourth-generation cephalosporins for
ceftaroline [9]; vancomycin or teicoplanin for dalbavancin
[10]; levofloxacin for gatifloxacin, moxifloxacin, and
gemifloxacin [11]; and fluconazole or voriconazole for
posaconazole [12].
Linezolid, the only other commercially available oxazo-
lidinone, was first approved in the United States in
2000 and is now widely available in multiple commercial
susceptibility testing products. We evaluated the useful-
ness of linezolid as a surrogate agent for predicting the
susceptibility of clinically significant Gram-positive patho-
gens to tedizolid.
Material and methods
Sources for bacterial strains
A total of 10,702 Gram-positive isolates were obtained
from annual surveillance programs, from 3 clinical trials
of tedizolid for treatment of ABSSSI, and from a preclin-
ical study of tedizolid activity that included linezolid-
resistant isolates. The surveillance isolates included 9022
Gram-positive clinical isolates collected from sites in
the United States, Belgium, Czech Republic, France,
Germany, Hungary, Italy, Spain, Sweden, and United
Kingdom from 2009 through 2012. A total of 937 isolates
were collected between 2008 and 2013 from a US-
based phase 2 and from 2 multinational phase 3 clinical
trials of tedizolid (NCT01519778, NCT0117022, and
NCT01421511). An additional 743 isolates were collected
in the United States as part of a preclinical study to
evaluate the antibacterial activity of tedizolid [1]. Over-
all, the isolates included in this study were composed of
the following groupings: S. aureus (n = 7187), staphylococci
other than S. aureus (n = 674), Enterococcus spp (n = 1241),
and Streptococcus spp (n = 1600).
Susceptibility testing
Susceptibility testing was performed using the reference
broth microdilution method in accordance with the
guidelines of the Clinical and Laboratory Standards
Institute (CLSI) [13]. Tedizolid was supplied by Cubist
Pharmaceuticals (San Diego, CA); ThermoFisher Scientific
(Cleveland, OH) produced the broth microdilution panels
for the annual surveillance programs and the clinical trials;
Clinical Microbiology Institute (Wilsonville, OR) pro-
duced the broth microdilution panels for the preclinical
study [1]. Assay performance was monitored using
CLSI-recommended quality control strains S. aureus
ATCC 29213, Enterococcus faecalis ATCC 29212, and
Streptococcus pneumoniae ATCC 49619.Analyses
For select organism groupings, the minimum inhibitory
concentration (MIC) results for tedizolid were directly
compared with those for linezolid using scatter plots. The
FDA approved the following tedizolid breakpoints:
≤0.5 μg/ml (susceptible), 1 μg/ml (intermediate), and
≥2 μg/ml (resistant) for S. aureus (including MRSA iso-
lates); ≤0.5 μg/ml (susceptible) for Streptococcus pyogenes,
Streptococcus agalactiae, and E. faecalis; and ≤0.25 μg/ml
(susceptible) for Streptococcus anginosus group isolates
(ie, S. anginosus, S. intermedius, and S. constellatus) [7].
For the analyses presented in the current study, the fol-
lowing tedizolid breakpoints were applied: ≤0.5 μg/ml
(susceptible), 1 μg/ml (intermediate), and ≥2 μg/ml
(resistant) for staphylococci; ≤0.5 μg/ml (susceptible)
and ≥1 μg/ml (nonsusceptible) for streptococci and en-
terococci; and ≤0.25 μg/ml (susceptible) and ≥0.5 μg/ml
(nonsusceptible) for analysis of only the S. anginosus
group isolates. Current CLSI breakpoints were applied
for linezolid [14].
The definitions of errors in these analyses were (1)
very major error (ie, a false-susceptible error in which a
susceptible result was obtained for linezolid and a resistant
[or nonsusceptible] result was obtained for tedizolid); (2)
major error (ie, a false-resistant error in which a resistant
[or nonsusceptible] result was obtained for linezolid and a
susceptible result was obtained for tedizolid); and (3)
minor error (ie, result for one of the agents was intermedi-
ate and the other agent was susceptible, nonsusceptible,
or resistant) [15]. Error rates were calculated separately
for each organism grouping using the total number of iso-
lates in the respective grouping as the denominator.
Results
MIC distributions
Table 1 summarizes the cumulative inhibition across the
MIC range stratified by organism grouping for tedizolid
and linezolid. MIC results for the CLSI quality control
strains were within CLSI-recommended ranges for both
test agents (data not shown) [14]. The minimum inhibi-
tory concentrations required to inhibit the growth of 90%
of organisms (MIC90 values) were 0.5 and 2 μg/ml or less
for tedizolid and linezolid, respectively. Isolates resistant
to linezolid (S. aureus [n = 20], non-S. aureus staphylo-
cocci [n = 6], Enterococcus spp [n = 4], and Streptococcus
spp [n = 1]) were predominantly contributed by the pre-
clinical study [1]. Linezolid-resistant isolates were rarely
isolated in surveillance studies and were not present
among patients in the clinical program.
Linezolid as a surrogate for tedizolid susceptibility when
testing S. aureus isolates
For 7187 S. aureus isolates, the very major error rate was
0%, with no isolate showing susceptibility to linezolid
Table 1 Cumulative inhibition at MIC values by organism grouping and antimicrobial agent
Organism grouping (no. tested) Cumulative number (%) of isolates inhibited at MIC value (μg/ml)
Antimicrobial agent ≤0.06 0.12 0.25a 0.5 1 2 4 8 >8
S. aureus (7187)
Tedizolid 17 (0.2) 550 (7.7) 5024(69.9) 7163 (99.6) 7175 (99.8) 7180 (99.9) 7184 (99.9) 7186 (99.9) 7187 (100)
Linezolid – – 7 (0.1) 29 (0.4) 1580 (21.9) 6813 (94.7) 7167 (99.7) 7170 (99.7) 7187 (100)
Staphylococcal species (non-S. aureus)b (674)
Tedizolid 30 (4.5) 323 (47.9) 597 (88.5) 664 (98.5) 669 (99.2) 669 (99.2) 673 (99.8) 674 (100) 674 (100)
Linezolid – – 6 (0.9) 163 (24.1) 575 (85.3) 660 (97.9) 668 (99.1) 669 (99.2) 674 (100)
Enterococcus spp. (1241)
Tedizolid 8 (0.6) 71 (5.7) 701 (56.4) 1224 (98.6) 1237 (99.6) 1240 (99.9) 1241 (100) 1241 (100) 1241 (100)
Linezolid – – 5 (0.4) 39 (3.1) 544 (43.8) 1219 (98.2) 1237 (99.6) 1238 (99.7) 1241 (100)
Streptococcus spp. (1600)
Tedizolid 80 (5.0) 790 (49.3) 1592 (99.5) 1600 (100) 1600 (100) 1600 (100) 1600 (100) 1600 (100) 1600 (100)
Linezolid – – 56 (3.5) 474 (29.6) 1516 (94.7) 1599 (99.9) 1600 (100) 1600 (100) 1600 (100)
Streptococcus anginosus groupc (91)
Tedizolid 35 (38.4) 75 (82.4) 91 (100) 91 (100) 91 (100) 91 (100) 91 (100) 91 (100) 91 (100)
Linezolid – – 35 (38.4) 67 (73.6) 91 (100) 91 (100) 91 (100) 91 (100) 91 (100)
Abbreviations: MIC minimum inhibitory concentration, MIC50 MIC required to inhibit growth of 50% of isolates, MIC90 MIC required to inhibit growth of 90% of isolates.
Italics indicate MIC50.
Bolding indicates MIC90.
aAn MIC value of 0.25 was the lowest MIC value tested for linezolid. Linezolid results should be read as ≤0.25 μg/ml.bIncludes isolates of S. capitis (28), S. caprae (4),
S. cohnii (2), S. epidermidis (405), S. haemolyticus (52), S. hominis (56), S. intermedius (7), S. lugdunensis (47), S. pasteuri (1), S. pettenkoferi (1), S. saprophyticus (28), S. schleiferi
(6), S. simulans (14), S. warneri (12), S. xylosus (2), and unspeciated coagulase-negative Staphylococcus spp. (9).
cIncludes isolates of S. anginosus, S. intermedius, and S. constellatus.
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(false-resistant error) was shown for 4 isolates (0.06%). A
minor error was noted for 12 isolates (0.2%) that showed
intermediate susceptibility to tedizolid but were either
linezolid susceptible (n = 8) or linezolid resistant (n = 4).
Categorical agreement was 99.8% (7171 of 7187 isolates).
Linezolid as a surrogate for tedizolid susceptibility when
testing staphylococcal isolates other than S. aureus
Among 674 isolates of staphylococcal species other than
S. aureus, no very major errors (false-susceptible) or
major errors (false-resistant) were noted when break-
points ≤0.5 μg/ml (susceptible), 1 μg/ml (intermediate),
and ≥2 μg/ml (resistant) were applied (Figure 2). A minor
error was reported for 5 isolates (0.7%), which showed
intermediate susceptibility to tedizolid but were suscep-
tible to linezolid (n = 4) or resistant to linezolid (n = 1).
Categorical agreement was 99.3% (669 of 674 isolates).
The staphylococcal isolates in this organism grouping
were predominantly from coagulase-negative species.
Linezolid as a surrogate for tedizolid susceptibility when
testing enterococcal isolates
To analyze the 1241 enterococcal isolates (predomin-
antly isolates of E. faecalis and E. faecium, including
vancomycin-resistant isolates of both species), a break-
point ≤0.5 μg/ml (susceptible) was applied (Figure 3).Three isolates (0.2%) exhibited a very major error, which
were susceptible to linezolid (MIC, 2 μg/ml) but nonsus-
ceptible to tedizolid (MIC, 1 μg/ml). A minor error was
reported for 18 isolates (1.5%), which displayed inter-
mediate resistance to linezolid but were susceptible
(n = 8) or nonsusceptible (n = 10) to tedizolid. Categorical
agreement was 98.3% (1220 of 1241 isolates).Linezolid as a surrogate candidate for streptococci
All streptococcal isolates tested (n = 1600) were susceptible
to tedizolid when a breakpoint ≤0.5 μg/ml (susceptible) was
applied (Figure 4). The streptococcal isolates included a
mix of species, including S. pyogenes, S. agalactiae; Lance-
field groups C, F, and G; and viridans group isolates. A
major error was seen for a single isolate of S. agalactiae
(0.06%), which was linezolid resistant (MIC, 4 μg/ml) but
tedizolid susceptible (MIC, 0.5 μg/ml). There were no very
major errors or minor errors. Categorical agreement was
99.9% (1599 of 1600 isolates).
The subset of isolates (n = 91) confirmed to be members
of the S. anginosus group (ie, S. anginosus, S. constellatus,
and S. intermedius) were analyzed separately using the
FDA-approved breakpoint for tedizolid of ≤0.25 μg/ml
(susceptible) (Figure 5). All isolates were susceptible to
tedizolid and linezolid both by these criteria; therefore,
there were no interpretive errors.
Figure 2 Scatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 674 staphylococcal isolates
other than Staphylococcus aureus. Dashed lines represent the US Food and Drug Administration–approved S. aureus breakpoints for tedizolid
generalized for all staphylococci (≤0.5 μg/ml [susceptible], 1 μg/ml [intermediate], and ≥2 μg/ml [resistant]) and the Clinical and Laboratory
Standards Institute–approved breakpoints for linezolid (≤4 μg/ml [susceptible] and ≥8 μg/ml [resistant]). These isolates are primarily from
coagulase-negative staphylococcal species (eg, S. epidermidis, S. haemolyticus, S. lugdunensis), though some isolates are from coagulase-positive
staphylococcal species other than S. aureus.
Figure 1 Scatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 7187 Staphylococcus aureus
isolates. Dashed lines represent the breakpoints for tedizolid (≤0.5 μg/ml [susceptible], 1 μg/ml [intermediate], and ≥2 μg/ml [resistant]) and
linezolid (≤4 μg/ml [susceptible] and ≥8 μg/ml [resistant]).
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Figure 3 Scatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 1241 enterococcal isolates.
Dashed lines represent the US Food and Drug Administration–approved Enterococcus faecalis breakpoint for tedizolid generalized for all
enterococci (≤0.5 μg/ml [susceptible]) and the Clinical and Laboratory Standards Institute–approved breakpoints for linezolid (≤2 μg/ml
[susceptible], 4 μg/ml [intermediate], and ≥8 μg/ml [resistant]).
Figure 4 Scatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 1600 streptococcal isolates.
Dashed lines represent the US Food and Drug Administration–approved Streptococcus pyogenes and Streptococcus agalactiae breakpoint for
tedizolid generalized for all streptococci (≤0.5 μg/ml [susceptible]) and the Clinical and Laboratory Standards Institute–approved breakpoint for
linezolid (≤2 μg/ml [susceptible]).
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Figure 5 Scatter plot comparing tedizolid and linezolid minimum inhibitory concentration (MIC) values for 91 Streptococcus anginosus
group isolates. Dashed lines represent the US Food and Drug Administration–approved breakpoint for tedizolid for S. anginosus group isolates
(≤0.25 μg/ml [susceptible]) and the Clinical and Laboratory Standards Institute–approved breakpoint for linezolid (≤2 μg/ml [susceptible]).
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Tedizolid is a novel oxazolidinone approved by the FDA
for management of ABSSSI caused by certain susceptible
Gram-positive pathogens, and is in further clinical devel-
opment for management of nosocomial pneumonia.
Tedizolid represents a potentially valuable therapeutic
addition to the antimicrobial agents currently used for
management of ABSSSI; however, FDA-approved com-
mercial products for tedizolid susceptibility testing are
currently unavailable. This analysis demonstrated that
linezolid, the only oxazolidinone available in commercial
susceptibility testing products [16], can serve as a surro-
gate agent to predict tedizolid susceptibility of clinically
relevant Gram-positive pathogens.
For all organism groupings tested (S. aureus, staphylo-
cocci other than S. aureus, Enterococcus spp, Streptococcus
spp, and S. anginosus group), linezolid susceptibility was
highly predictive of tedizolid susceptibility. For all patho-
gen groups, the categorical agreement between test results
for tedizolid and linezolid was >98%, and rates of very
major and major errors were well within the CLSI limits
of acceptability (ie, very major and major error rates of
≤1.5% and ≤3%, respectively) [15]. Recommendations
from previous studies indicate that absolute categorical
agreement rates of ≥90% are essential and rates of ≥95%
are preferred [10,12]. In this study, the risk for very major
error where an isolate would be reported as susceptible
despite being resistant or nonsusceptible was rare and
was highest for Enterococcus spp, which had a reportedvery major error rate of only 0.2%. The FDA-approved
breakpoints for tedizolid were derived from MIC popula-
tion distributions, pharmacokinetic/pharmacodynamics
information, Monte Carlo simulations, and clinical and
microbiological outcome data from the ABSSSI clinical
program.
The main mechanisms for linezolid resistance consist of
mutations in chromosomal genes encoding 23S ribosomal
RNA and ribosomal proteins L3 and L4, or the presence
of the plasmid-borne cfr gene. Although tedizolid MIC
values are affected by chromosomal mutations, tedizolid
has been shown to retain antimicrobial activity against
strains with the cfr gene [17-19]. When linezolid is used as
a surrogate testing agent for tedizolid, cfr-positive isolates
will likely result in major errors (false resistance or false
nonsusceptible). In these rare instances, the major errors
should not adversely affect patient care because a labora-
tory result of resistant or nonsusceptible to tedizolid
should preclude the use of the agent in these situations.
Clinical laboratories have successfully used a class repre-
sentative to predict susceptibility to other agents in the
same class as a practical alternative when specific suscep-
tibility testing products are unavailable [8-12]. Given the
lack of such products for tedizolid, this approach provides
a useful strategy to assist in the appropriate therapeutic
use of tedizolid against clinically important Gram-positive
pathogens. As commercial tedizolid susceptibility products
become available, they could rapidly replace the interim use
of linezolid as the surrogate testing agent.
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This analysis showed that, for all Gram-positive patho-
gen groups tested, there was high categorical agreement
between tedizolid and linezolid susceptibility results, and
rates of very major errors and major errors were well
within acceptable limits. These findings show that linezolid
can be used as a reliable surrogate to predict susceptibility
testing results for tedizolid against clinically relevant
Gram-positive pathogens. Consideration should be given
to the use of linezolid as a surrogate so susceptibility
testing results for tedizolid can be made rapidly available
to health care providers.
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